story of the week
Nivolumab in Advanced Gastric or Gastroesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2017 Oct 05;[EPub Ahead of Print], YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, K Muro, WK Kang, KH Yeh, T Yoshikawa, SC Oh, LY Bai, T Tamura, KW Lee, Y Hamamoto, JG Kim, K Chin, DY Oh, K Minashi, JY Cho, M Tsuda, LT ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.